Citius Oncology (CTOR) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed Citius Oncology (CTOR) over the past year, losing 18.2% versus a loss of 54.6%. Citius Oncology is the larger company by market cap ($88.3 million vs $56.1 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | TLPH |
|---|---|---|
| Share price | $0.835 | $1.08 |
| Market cap | $88.31M | $56.06M |
| 1-day change | -2.45% | +2.86% |
| YTD return | -16.50% | -5.26% |
| 1-year return | -54.62% | -18.18% |
| 5-year return | — | -94.71% |
| EPS (TTM) | $-0.48 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $1.57 |
| 52-week low | $0.491 | $0.69 |
| Distance from 52-week high | -62.89% | -31.21% |
| Analyst consensus | none | none |
| Avg. price target upside | +379.04% | +189.81% |
| Average volume | 99.72K | 238.38K |
| Shares outstanding | 105.76M | 51.91M |
| Employees | — | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed CTOR by 36.4 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Healthcare · Drug Manufacturers - Specialty & Generic
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
CTOR vs TLPH FAQ
Which is bigger, Citius Oncology or Talphera?
Citius Oncology (CTOR) is larger, with a market capitalization of $88.31M compared with $56.06M for Talphera (TLPH).
Which stock has performed better over the past year, CTOR or TLPH?
TLPH returned -18.18% over the past 12 months, compared with -54.62% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and Talphera in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.